MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Wednesday, May 9, 2012

Alemtuzumab (Campath) Heads for Regulatory Review in MS


Susan Jeffrey
May 7, 2012 (New Orleans, Louisiana) — Full results of a second phase 3 trial of alemtuzumab (Lemtrada, Genzyme/Sanofi) in patients with relapsing-remitting multiple sclerosis (MS) who had relapsed while receiving previous treatment show that the still-investigational treatment met both co-primary endpoints of reductions in relapse rates and sustained accumulation of disability compared with standard therapy with interferon beta-1a (Rebif, EMD Serono/Pfizer).
The findings, from the Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis 2 (CARE-MS 2) trial, were presented here at the American Academy of Neurology's 64th Annual Meeting. Topline results were released in November 2011 and reported by Medscape Medical News at that time. The study was funded by Genzyme.
"This study shows superior efficacy of alemtuzumab compared to interferon beta-1a across multiple outcomes, including relapses, disability — not only reduced risk of worsening, but increased likelihood of improvement — and on MRI lesion activity and brain volume loss," said Jeffrey Cohen, director of experimental therapeutics, Cleveland Clinic Mellen Center for MS Treatment and Research, Ohio, and a member of the Steering Committee, who presented the results here.
CARE-MS 2 is the third positive study comparing alemtuzumab with an active comparator, interferon beta-1a, "which itself is effective against relapses, disability, and MRI [magnetic resonance imaging]" activity, Dr. Cohen noted. "The adverse event profile was consistent with previous studies, he added, and a program to monitor for development of thyroid issues and immune thrombocytopenia (ITP) was successful in early detection of these known complications.
Alasdair Coles, MD, senior lecturer in the Department of Clinical Neurosciences at the University of Cambridge, United Kingdom (UK), was principal investigator of the CARE-MS 1 trial that compared alemtuzumab with interferon beta-1a in treatment-naive patients. Results of that trial showed a significant reduction in relapse rates at 2 years but no significant effect on sustained accumulation of disability with alemtuzumab.
Dr. Coles told Medscape Medical News that results of these studies now form the basis for a new drug application to the US Food and Drug Administration (FDA) and to the European Medicines Agency (EMA).
Overall, alemtuzumab reduced lesions and delayed or even improved disability and in all trials was compared with active comparator; this, Dr. Coles noted, "has never been done before."
The package of alemtuzumab data is expected to be submitted to the FDA and EMA sometime in the second quarter this year, he said.


Posted by Stuart Schlossman

..
Comments are appreciated. Note that All comments are moderated 
 If not yet receiving our weekly e-Newsletter Click here to: REGISTER -
so that you can be kept up to date with MS News and Information
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
LIKE this BLOG? - Please click the LIKE button top left


..............................

No comments: